drugset / Trial / NCT00291876

Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Injected According to a 0, 12-month Schedule

NCT00291876

Phase 4 Completed 135 enrolled GlaxoSmithKline
NaSingle-groupOpen-labelPrevention

Summary

The aim of this study is to evaluate the persistence of hepatitis A antibodies at 138, 150, 162, 174,186, 198, 210, 222, 234 and 246 months after subjects received their first dose of a 2 dose vaccination schedule of hepatitis A vaccine. This protocol posting deals with objectives \& outcome measures of the extension phase at year 11 to 20. No additional subjects will be recruited during this long-term follow-up.

Timeline

Start
2004-01-01
Primary completion
2013-03-01
Completion
2013-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Havrix Vaccine Other